Search 

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Catalyst is a clinical research organisation (CRO)that provides highly customisable solutions to the global biopharmaceutical industry through two established, branded solutions: CatalystOncology and Catalyst Flex. The company provides multi-therapeutic global resourcing and functional services through Catalyst Flex, and full-service oncology CRO offerings through Catalyst Oncology.

With over 800 staff andoffices in the United States and Europe, Catalyst's flexible service model isbuilt from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies.

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

• 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
• GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
• Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
• GLP Analysis Certification and Problem Solving including GLP NMR 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Evotec has been a leader in drug discovery and development for over 30 years, offering end-to-end solutions from target identification to clinical trials. Their innovative approach leverages deep disease understanding, cutting-edge technologies, and tailored solutions, supporting collaborations through standalone services, integrated programs, or strategic partnerships to create impactful medicines.

HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers; they help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Their experienced scientific team work as an extension of your in-house team and provide specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis services.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.

Onyx Scientific is a small molecule CDMO specialising in process R&D, non-GMP scale up and GMP manufacture for clinical trials and commercial. Good chemistry is at the core of everything we do. From our facilities in the UK and US, our teams of chemists will guide your small molecule API through development and manufacturing from the moment a lead molecule is identified, taking it into Phase I studies and right through to commercial manufacture.